Dr Reddys Laboratories Ltd (RDY) stock
Close on Nov 11, 2026Market cap $12.39BP/E 27.1Yield 0.57%
Dr Reddys Laboratories Ltd grew revenue 3.2% to ₹335.93B over fiscal 2026. Operating income fell 29.6% to ₹50.55B, moving the operating margin from 22.1% to 15.0%. Free cash flow was ₹33.43B, up 76.6% from a year earlier. At the latest close the market valued the company at ₹1.16T, 27.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Mar 31, 2026
Valuation
- Market cap
- ₹1.16T
- P/E ratio
- 27.1
- Price to sales
- 3.46
- Price to book
- 3.08
- Dividend yield
- 0.57%
- Free cash flow yield
- 2.87%
Fundamentals
- Revenue
- ₹335.93B
- Net income
- ₹42.85B
- EPS, diluted
- 51.42 INR
- Free cash flow
- ₹33.43B
Trading
- Previous close
- $14.86
- Open
- $14.67
- Day's range
- $14.61 – $14.84
- Volume
- 2,176,818
- Average volume (20 days)
- 2,955,319
- Beta (5 years)
- 0.35
- RSI (14 days)
- 72.8
- Volatility (1 year)
- 27.0%
- Relative volume
- 0.74×
- WACC
- 7.2%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | RDY | S&P 500 | Difference | RDY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +18.9% | -2.4% | +21.3 pts | ||
| 3 months | +19.2% | -1.2% | +20.3 pts | ||
| Year to date | +6.4% | +12.3% | −5.8 pts | ||
| 1 year | +8.2% | +12.4% | −4.2 pts | ||
| 3 years | +15.6% | +78.8% | −63.3 pts | +4.9% | +21.4% |
| 5 years | +19.9% | +75.2% | −55.3 pts | +3.7% | +11.9% |
| 10 years | +67.1% | +311.1% | −244.0 pts | +5.3% | +15.2% |
Eleven years at a glance
Fiscal years 2016 to 2026, INR
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Dr Reddys Laboratories filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Dr Reddys Laboratories
Pharmaceutical Preparations
Dr. Reddy’s Laboratories Limited is an integrated pharmaceutical company that develops, manufactures, and markets a broad portfolio of generic prescription drugs, over-the-counter medicines, biosimilars, and consumer healthcare products. The company operates across three reportable segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. Global Generics offers finished dosage forms ready for patient use, while PSAI supplies active pharmaceutical ingredients and provides custom contract research and manufacturing services. Its customer base includes patients, pharmacies, healthcare providers, innovator and biotechnology companies, and commercialization partners.
Company profile, executives and historyDr Reddys Laboratories stock: common questions
What is Dr Reddys Laboratories's stock price?
RDY closed at $14.84 on Nov 11, 2026, down 0.13% on the day.
What is Dr Reddys Laboratories's market cap?
Dr Reddys Laboratories was worth $12.39B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is RDY's P/E ratio?
RDY trades at 27.1 times earnings, based on diluted earnings per share of 51.42 INR over fiscal 2026.
How much revenue does Dr Reddys Laboratories make?
Dr Reddys Laboratories reported revenue of ₹335.93B for fiscal 2026, up 3.2% from a year earlier.
Does Dr Reddys Laboratories pay a dividend?
Yes. Dr Reddys Laboratories paid 8.00 INR per share over the last twelve months, a yield of 0.57% at the latest price.
How has RDY stock performed over the past year?
Including dividends, RDY returned +8.2% over the past year, against +12.4% for the S&P 500.
Who are Dr Reddys Laboratories's competitors?
Companies most similar to Dr Reddys Laboratories by business, industry and size include NVO, LLY, MRK, JNJ, ABBV.
See a number that looks wrong?